Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why

18.06.24 00:15 Uhr

Werte in diesem Artikel
Aktien

146,40 EUR 2,55 EUR 1,77%

Indizes

8.198,8 PKT 43,1 PKT 0,53%

4.495,5 PKT 22,0 PKT 0,49%

7.393,3 PKT -65,0 PKT -0,87%

2.800,2 PKT 17,2 PKT 0,62%

2.593,4 PKT 22,8 PKT 0,89%

1.002,2 PKT 9,2 PKT 0,93%

4.462,6 PKT 47,2 PKT 1,07%

Astrazeneca (AZN) closed at $79.31 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily gain of 0.77%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.95%.The pharmaceutical's shares have seen an increase of 3.5% over the last month, surpassing the Medical sector's gain of 1.49% and falling behind the S&P 500's gain of 3.71%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.98, reflecting a 9.26% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.49 billion, indicating a 9.4% increase compared to the same quarter of the previous year.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.04 per share and a revenue of $51.78 billion, indicating changes of +11.29% and +13.03%, respectively, from the former year.Investors should also pay attention to any latest changes in analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.25% higher within the past month. Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 19.72. This indicates a premium in contrast to its industry's Forward P/E of 14.54.One should further note that AZN currently holds a PEG ratio of 1.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 149, placing it within the bottom 41% of over 250 industries.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.Highest Returns for Any Asset ClassIt’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.Hurry, Download Special Report – It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu AstraZeneca PLC

Analysen zu AstraZeneca PLC

DatumRatingAnalyst
10.07.2024AstraZeneca HoldDeutsche Bank AG
10.07.2024AstraZeneca OverweightJP Morgan Chase & Co.
04.07.2024AstraZeneca BuyGoldman Sachs Group Inc.
03.07.2024AstraZeneca BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.07.2024AstraZeneca HoldJefferies & Company Inc.
DatumRatingAnalyst
10.07.2024AstraZeneca OverweightJP Morgan Chase & Co.
04.07.2024AstraZeneca BuyGoldman Sachs Group Inc.
03.07.2024AstraZeneca BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
25.06.2024AstraZeneca BuyGoldman Sachs Group Inc.
24.06.2024AstraZeneca OverweightBarclays Capital
DatumRatingAnalyst
10.07.2024AstraZeneca HoldDeutsche Bank AG
02.07.2024AstraZeneca HoldJefferies & Company Inc.
26.06.2024AstraZeneca HoldDeutsche Bank AG
05.06.2024AstraZeneca HoldDeutsche Bank AG
22.05.2024AstraZeneca HoldDeutsche Bank AG
DatumRatingAnalyst
04.06.2024AstraZeneca SellUBS AG
21.05.2024AstraZeneca SellUBS AG
15.05.2024AstraZeneca SellUBS AG
26.04.2024AstraZeneca SellUBS AG
25.04.2024AstraZeneca SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"